ArticleNature medicine2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02546661 (An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer), which is not on this map. Cited by 65 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 2 pooled it
18.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis.Frontiers in oncology · 2024Pooled it
- PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety.Bladder cancer (Amsterdam, Netherlands) · 2023Pooled it
- Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.Nature medicine · 2024Trial
- Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Trial
- Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.Nature medicine · 2022Trial
- DNA damage response pathway alterations in urothelial carcinoma: a road to precision oncology or a dead-end street?The oncologist · 2026Review
- Integrative multi-omics and single-cell analysis identifies EGFR pathway activation and metabolic reprogramming as potential synthetic lethal vulnerabilities in resistance to the FGFR inhibitor AZD4547.Journal of translational medicine · 2026Article
- The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.Current opinion in urology · 2026Review
- Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107.Molecular oncology · 2026Article
- Towards biomarker-driven therapies for urothelial carcinoma.Nature reviews. Clinical oncology · 2026Review
- Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers.Frontiers in oncology · 2026Review
- Germline whole-exome sequencing revealsJournal for immunotherapy of cancer · 2025Article
- PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition.Frontiers in oncology · 2025Review
- The role of circulating tumor DNA (ctDNA) in urothelial cancers.Exploration of targeted anti-tumor therapy · 2025Article
- Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.Frontiers in immunology · 2025Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
24 authors at 17 institutions in 5 countries.
Thomas PowlesBarts Cancer Institute, QMUL, Barts Cancer Centre, London, UK. Thomas.Powles@bartshealth.nhs.uk.ORCID http://orcid.org/0000-0001-7760-4724
Danielle CarrollAstraZeneca IMED Biotech Unit, Cambridge, UK.
Simon ChowdhuryGuys and St Thomas' Hospital, London, UK.
Gwenaelle GravisInstitute Paoli-Calmettes, Marseille, France.
Florence JolyUNICANCER, Centre Léon Bérard, Lyons, France.
Joan CarlesVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Aude FléchonCentre Léon Bérard, Lyon, France.
Pablo MarotoHospital de la Santa Creu i San Pau, Barcelona, Spain.
Daniel PetrylakYale School of Medicine, New Haven, CT, USA.
Frédéric RollandInstitut de Cancerologie de l'Ouest, Saint-Herblain, France.ORCID http://orcid.org/0000-0001-6957-0894
Natalie CookThe Christie NHS Foundation Trust and The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0003-2606-1082
Arjun V BalarPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Srikala S SridharPrincess Margaret Hospital, Toronto, Ontario, Canada.
Matthew D GalskyIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Petros GrivasUniversity of Washington, Seattle, WA, USA.
Alain RavaudBordeaux University Hospital, Bordeaux, France.
Robert JonesUniversity of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.ORCID http://orcid.org/0000-0002-2904-6980
Jan CosaertAstraZeneca Oncology R&D, Research and Early Development, Cambridge, UK.
Darren HodgsonAstraZeneca IMED Biotech Unit, Cambridge, UK.
Iwanka KozarewaAstraZeneca IMED Biotech Unit, Cambridge, UK.
Richard MatherAstraZeneca Oncology R&D, Research and Early Development, Cambridge, UK.
Robert McEwenAstraZeneca IMED Biotech Unit, Cambridge, UK.
Florence MercierAstraZeneca Oncology R&D, Research and Early Development, Cambridge, UK.
Dónal LandersCRUK Manchester Institute Cancer Biomarker Centre, Manchester, UK.ORCID http://orcid.org/0000-0001-8376-9779
AstraZeneca (United Kingdom) · GBCentre Léon Bérard · FRBeatson West of Scotland Cancer Centre · GBBordeaux Population Health · FRCancer Research UK Manchester Institute · GBHospital de Sant Pau · ESIcahn School of Medicine at Mount Sinai · USInstitut de Cancérologie de l'Ouest · FRInstitut Paoli-Calmettes · FRNYU Langone Health · USPrincess Margaret Cancer Centre · CAQueen Mary University of London · GBSt Thomas' Hospital · GBUniversity of Manchester · GBUniversity of Washington · USVall d'Hebron Hospital Universitari · ESYale University · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC)
Indexed as
Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBenzamidesBiomarkers, TumorHumansMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Molecular Targeted TherapyMorpholinesPhosphatidylinositol 3-KinasesPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Progression-Free SurvivalAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalB7-H1 AntigenBenzamidesBiomarkers, TumorCD274 protein, humandurvalumabMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MorpholinesMTOR protein, humanolaparibPARP1 protein, humanPhosphatidylinositol 3-KinasesPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1PyrimidinesReceptors, Fibroblast Growth FactorTOR Serine-Threonine Kinasesvistusertib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02546661ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.